Policy | March 14, 2022
Draft policy on medical devices released
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
It will be the first and only global office for traditional medicine in the world
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Subscribe To Our Newsletter & Stay Updated
